What does the public data reveal about the Boehringer Ingelheim veterinary portfolio, and what should a veterinary clinic owner, practice manager, regulatory affairs specialist, or clinical director do with it?

Boehringer Ingelheim Animal Health, a division of the family-owned German pharmaceutical corporation, occupies a prominent role in both companion animal therapeutics and food-animal preventive medicine. The company’s portfolio is defined by major companion animal brands—such as the NexGard parasiticide family, Vetmedin for cardiovascular support, and the novel endocrine therapeutic Senvelgo—alongside swine and poultry biological lines like Ingelvac. For practice owners and clinical directors, understanding the safety profiles, clinical monitoring guidelines, and regulatory nuances of these therapies is critical for optimizing patient outcomes and managing pharmacy workflows.

This dossier analyzes the Boehringer Ingelheim veterinary portfolio using official records from the United States Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) and the European Medicines Agency (EMA), together with aggregated post-market pharmacovigilance data from the FDA CVM public adverse-event database. It details the clinical integration and safety boundaries of SGLT2 inhibitor therapy in cats, the Stage B2 staging rules behind Vetmedin's preclinical indication, and the regulatory landscape of its centrally authorized vaccines. Where VetMedGuide already publishes a product-specific deep dive, this dossier links to it rather than restating the detail.

---

Fast Answer

What is the therapeutic scope of the Boehringer Ingelheim veterinary portfolio, and what does clinical safety data reveal about its core ingredients?

Boehringer Ingelheim's portfolio is structured around three primary therapeutic areas: parasite protection (NexGard, Heartgard), chronic disease management (Vetmedin, Semintra, Senvelgo), and livestock immunizations (Ingelvac). A key recent innovation is Senvelgo (velagliflozin), a liquid oral SGLT2 inhibitor that has changed feline diabetes mellitus management.

An analysis of the FDA CVM public adverse-event database (a public extract dated June 2026 containing 1.34 million reports) identifies 78,516 unique reports naming Boehringer Ingelheim's four core companion-animal active ingredients shown below (afoxolaner, pimobendan, telmisartan, velagliflozin). About 29% (22,888) of those carry a serious adverse-event flag. The reporting volume is dominated by the isoxazoline afoxolaner (NexGard), which accounts for 67,556 reports, and the inodilator pimobendan (Vetmedin), which accounts for 6,475 reports.

These metrics reflect passive reporting patterns — complaints submitted by veterinarians and owners — and do not confirm direct causation or establish incidence rates, because the total number of animals treated is not public. They do define the clinical boundaries of post-market surveillance. For veterinary practitioners, the practical takeaway is that while blockbuster therapies like NexGard offer reliable parasite control and Senvelgo simplifies feline diabetic management, they require strict patient pre-screening — checking for neurological histories before prescribing isoxazolines and monitoring closely for diabetic ketoacidosis (DKA) when initiating SGLT2 inhibitors.

---

What are the core diagnostic and treatment categories of Boehringer Ingelheim?

The global footprint of Boehringer Ingelheim Animal Health is divided into two primary segments: companion animal medicine and livestock biosecurity.

                  ┌──────────────────────────────────────────┐
                  │   Boehringer Ingelheim Vet Portfolio     │
                  └────────────────────┬─────────────────────┘
                                       │
         ┌───────────────┬─────────────┴─────────────┬───────────────┐
         ▼               ▼                           ▼               ▼
   Parasiticides    Endocrine & Cardiac         Biologics      Therapeutics
   (NexGard/Chews)  (Senvelgo/Vetmedin)         (Ingelvac)     (Metacam/Oral)

1. Parasite Protection (NexGard and Heartgard)

The parasiticide portfolio is anchored by:

• Afoxolaner (NexGard): An isoxazoline-class insecticide and acaricide that blocks GABA-gated chloride channels. It is marketed as a standalone chewable and in combination with milbemycin oxime (NexGard PLUS) for canine protection, and as a broad-spectrum topical solution (NexGard COMBO) containing esafoxolaner, eprinomectin, and praziquantel for feline patients.
• Ivermectin and Pyrantel Pamoate (Heartgard Plus): The historical standard for monthly canine heartworm prevention and treatment of hookworms and ascarids.

2. Chronic Disease and Endocrine Management

Boehringer has positioned itself as a pioneer in chronic feline and canine care:

• Velagliflozin (Senvelgo): A sodium-glucose cotransporter 2 (SGLT2) inhibitor marketed as a once-daily liquid oral solution for feline diabetes mellitus.
• Pimobendan (Vetmedin): An inodilator (calcium sensitizer and phosphodiesterase 3 inhibitor) approved to manage congestive heart failure (CHF) and delay the onset of CHF in dogs with preclinical mitral valve disease.
• Telmisartan (Semintra): An angiotensin II receptor blocker (ARB) approved to treat feline systemic hypertension and reduce proteinuria associated with chronic kidney disease (CKD) in cats.

3. Biologicals (Swine and Livestock Vaccines)

Boehringer Ingelheim is one of the largest livestock vaccine manufacturers globally, focusing on intensive production swine and cattle:

• Ingelvac PCV FLEX / Ingelvac PRRS: Swine vaccines targeting Porcine Circovirus Type 2 (PCV2) and Porcine Reproductive and Respiratory Syndrome (PRRS) virus.
• Bovela: A centrally authorized vaccine in Europe containing modified live non-cytopathic Bovine Viral Diarrhea Virus (BVDV) types 1 and 2, providing fetal protection in cattle.

4. Therapeutics and Pain Management

• Meloxicam (Metacam): A nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class, targeting COX-2. It is widely used in dogs for osteoarthritis pain and in cats as a single-dose postoperative analgesic.

---

How do afoxolaner (NexGard) and pimobendan (Vetmedin) perform in safety databases?

An evaluation of the public safety database maintained by the FDA CVM (a public extract dated June 2026, containing 1.34 million reports) reveals distinct reporting profiles for Boehringer Ingelheim's flagship products. Clinicians must remember that these reports represent passive surveillance complaints — they do not establish baseline incidence rates (the denominator of treated animals is not public) and do not prove the drug caused the sign.

Aggregated across the four core companion-animal active ingredients below, the database holds 78,516 unique reports, of which about 29% carry a serious adverse-event flag and roughly 4% list a fatal outcome (Died or Euthanized). Report counts are matched on active_ingredient (brand names are masked in the public file) and de-duplicated by unique report ID.

Boehringer Ingelheim Ingredient Performance Matrix

Active Ingredient (Brand Name)	Total Reports	Serious Adverse Events	Serious AE %	Top Reported Clinical Signs
Afoxolaner (NexGard)	67,556	20,199	29.9%	Vomiting, diarrhea, lethargy, lack of efficacy (tick/flea), seizures, ataxia.
Pimobendan (Vetmedin)	6,475	1,862	28.8%	Vomiting, diarrhea, lethargy, death, cough, anorexia, death by euthanasia.
Telmisartan (Semintra)	670	230	34.3%	Vomiting, lack of efficacy, weight loss, diarrhea, elevated creatinine, decreased appetite.
Velagliflozin (Senvelgo)	4,088	646	15.8%	Ketosis, lack of efficacy, weight loss, diarrhea, vomiting, ketonuria, anorexia.

For product-specific safety detail, VetMedGuide publishes deeper analyses of Senvelgo and the SGLT2 class, Vetmedin staging and dosing, and NexGard side effects; this dossier focuses on the portfolio-level picture.

---

Pimobendan (Vetmedin) and the Stage B2 MMVD Indication

Pimobendan (Vetmedin) has long been the cornerstone of therapy for canine congestive heart failure secondary to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). However, the therapeutic landscape shifted following the publication of the EPIC Study (Evaluation of Pimobendan in Dogs with Cardiomegaly), which demonstrated that pimobendan delays the onset of heart failure in dogs with preclinical disease.

The Stage B2 Indication

Under ACVIM guidelines, MMVD is staged from A to D. Stage B represents dogs with structural heart disease (murmur) who have never shown clinical signs of CHF:

• Stage B1: Hemodynamically insignificant disease; no radiographic or echocardiographic evidence of cardiac enlargement. Pimobendan is not indicated.
• Stage B2: Hemodynamically significant disease; evidence of cardiac enlargement meeting specific criteria.

Determining Echocardiographic and Radiographic Staging Metrics

To legally prescribe and clinically justify starting Vetmedin in a preclinical dog, the patient must meet the following criteria:

1. Murmur Intensity: A systolic murmur graded at least 3/6 or louder, loudest over the mitral valve area.
2. Vertebral Heart Size (VHS): Radiographic cardiomegaly demonstrated by a VHS $> 10.5$ on a lateral thoracic radiograph (or vertebral left atrial size [VLAS] $\ge 3.0$).
3. Left Atrial size (LA:Ao Ratio): Echocardiographic left atrial enlargement demonstrated by a LA:Ao ratio $\ge 1.6$ measured in the short-axis view at the base of the heart.
4. Left Ventricular internal diameter (LVIDd): Echocardiographic left ventricular dilation demonstrated by a normalized LVIDd $\ge 1.7$ (LVIDd normalized to body weight according to the Cornell scaling method: $\text{LVIDd-N} = \text{LVIDd (cm)} / (\text{BW (kg)})^{0.294}$).

Pimobendan is FDA-approved to delay the onset of CHF in dogs meeting these Stage B2 criteria. The EPIC study demonstrated that administration at this stage extends the preclinical period by an average of 15 months (approximately 60% increase in time to onset of CHF).

From conditional to full FDA approval

The Stage B2 preclinical indication was initially granted on a conditional basis; as of December 2025 the FDA granted full approval for that indication based on two multi-site studies, including EPIC. Clinicians must perform accurate radiographic or echocardiographic staging prior to starting Vetmedin to ensure they are targeting Stage B2 patients rather than B1 — starting a B1 dog on pimobendan offers no demonstrated benefit.

---

What is the clinical significance of Senvelgo in feline endocrinology?

Senvelgo (velagliflozin oral solution) is a major innovation in veterinary endocrinology, approved as a once-daily liquid oral treatment for feline diabetes mellitus.

Mechanism of Action

Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. SGLT2 is located in the proximal convoluted tubules of the kidney and is responsible for reabsorbing approximately 90% of filtered glucose back into systemic circulation. By inhibiting SGLT2, velagliflozin prevents glucose reabsorption, leading to massive urinary glucose excretion (glucosuria) and a rapid reduction in blood glucose levels.

       [Filtrate in Renal Tubule] ──(SGLT2 Protein)──► [Systemic Reabsorption]
                                                           (90% Glucose Back)
                                                                   │
                                                                   ▼
       SGLT2 Inhibited (Senvelgo): ────────────────────────────────┼── (Reabsorption Blocked)
                                                                   │
                                                                   ▼
                                                         [Urinary Excretion]
                                                       Rapid Blood Glucose Drop.

Unlike traditional insulin therapy, which requires twice-daily subcutaneous injections, variable feeding schedules, and intensive glucose curve monitoring, velagliflozin:

• Is administered once daily as an oral solution, improving client compliance.
• Lowers blood glucose in a insulin-independent manner, reducing the risk of clinical hypoglycemia.
• Allows cats to be fed their normal diet without the requirement of feeding-dose synchronization.

---

SGLT2 Inhibitor Therapy: Clinical Monitoring and DKA Risks

Despite its benefits, velagliflozin carries a boxed warning due to the risk of diabetic ketoacidosis (DKA) and euglysemic diabetic ketoacidosis (eDKA). DKA is a life-threatening metabolic emergency caused by a relative insulin deficiency, leading the body to break down lipids into ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone) for energy, causing systemic acidosis.

Under SGLT2 inhibition, cats can develop euglycemic DKA. Because the kidneys are actively excreting glucose, blood glucose levels may appear normal or only mildly elevated (e.g., $< 250$ mg/dL), masking the underlying metabolic acidosis and severe ketonemia.

Feline SGLT2 Inhibitor Monitoring Pathway

                      ┌────────────────────────────────────────┐
                      │    Feline SGLT2 Inhibitor Candidate    │
                      └───────────────────┬────────────────────┘
                                          │
                        Perform Baseline Screening
                        (Ketones, Liver, Renal)
                                          │
                      ┌───────────────────┴───────────────────┐
                      ▼                                       ▼
             Insulin-Experienced?                   Blood Ketones >0.9 mmol/L?
             (Or clinically unstable)                (Or cachectic/sick)
                      │                                       │
                      ▼                                       ▼
              [DO NOT INITIATE]                      [DO NOT INITIATE]
            Risk of rapid DKA;                      Manage ketones first;
            Use insulin glargine.                   Re-screen when stable.
                      │                                       │
                      └───────────────────┬───────────────────┘
                                          │
                                          ▼
                                [Standard Candidate]
                          Initiate Senvelgo once daily;
                          Monitor blood ketones on days 2, 7, 14, 30.

1. Patient Selection Rules

• Otherwise Healthy Cats: Velagliflozin is indicated only for newly diagnosed diabetic cats that are clinically stable, hydrated, and eating.
• No Prior Insulin Treatment: It is not intended for use in cats previously treated with insulin. Cats transitioning from insulin have a significantly higher risk of developing DKA due to suppression of endogenous beta-cell insulin secretion; the label contraindicates the drug in insulin-pretreated cats.
• Ketone Screening: Do not initiate therapy in any cat with ketonuria or ketonemia, or with pancreatitis, anorexia, dehydration, or lethargy at diagnosis. The Boehringer Ingelheim Patient Management Guide defines the actionable cut-off as blood ketones at or above the upper end of the reference interval for the specific ketone meter or assay being used — the numeric threshold depends on the device, so it should be read off the meter's reference range rather than treated as a single universal number.

2. Transition and Monitoring Protocols

• Ketone Monitoring: Owners check urine ketones (dipstick) or blood beta-hydroxybutyrate roughly every 1–3 days across the first two weeks, with clinic rechecks around day 2/3, day 7, optionally day 14, and at week 4 — and any time the cat shows clinical signs of illness. The first two weeks are the highest-risk window; roughly 86% of ketosis/DKA episodes in the velagliflozin field trial occurred in that period.
• Discontinuation Rules: If ketones are detected at any point, or if the cat develops clinical signs of illness (lethargy, vomiting, anorexia, dehydration), the drug must be discontinued immediately, the patient evaluated by a veterinarian, hospitalized for fluid therapy, and transitioned to insulin. Do not wait to see whether ketones clear on their own.
• Hypoglycemia Risk: Although rare, hypoglycemia can occur. If blood glucose drops below 80 mg/dL, the dose should be adjusted, or the therapy suspended.

3. Treatment Protocol for SGLT2-Inhibitor-Induced Euglycemic DKA

If a cat on velagliflozin presents with euglycemic DKA, standard DKA protocols must be modified due to the presence of normal blood glucose levels:

• Discontinue SGLT2 Inhibitor immediately: Clear the drug from systemic circulation (half-life in cats is approximately 11 hours).
• Intravenous Fluid Therapy: Administer aggressive balanced crystalloid fluids (e.g., Plasmalyte or LRS) to correct dehydration, restore circulating volume, and promote renal clearance of ketones.
• Dextrose Supplementation: Because blood glucose is normal or only mildly elevated, initiate a continuous rate infusion (CRI) of dextrose (2.5% or 5%) immediately upon starting fluid therapy. This is necessary because insulin must be administered to shut down ketogenesis, and dextrose is required to prevent severe hypoglycemia.
• Insulin Therapy: Initiate a regular insulin CRI (or intermittent low-dose intramuscular regular insulin protocol) only after fluid therapy has restored perfusion and potassium levels are stabilized. Continue insulin administration until ketonemia is resolved and systemic pH is corrected, following the patient's ketone trend and acid–base status rather than a single fixed cut-off.
• Electrolyte Management: Monitor potassium and phosphorus levels every 4–6 hours. Insulin therapy drives potassium and phosphorus intracellularly, which can cause life-threatening hypokalemia or hypophosphatemia (resulting in hemolysis). Supplement IV fluids accordingly.

---

Therapeutics and Pain Management: Feline Meloxicam Protocol

Meloxicam (Metacam) is an effective analgesic, but its feline safety profile is highly dependent on regional regulatory guidelines and dosage structures:

• United States (FDA CVM): Metacam is approved in cats only as a single one-time subcutaneous injection (0.3 mg/kg) prior to surgery for postoperative pain (ovariohysterectomy, castration, orthopedic surgery). It carries a boxed warning against repeated oral use due to the risk of acute renal failure.
• European Union (EMA): Approves long-term oral meloxicam for the management of chronic musculoskeletal disorders. The dosing protocol involves a loading dose (0.1 mg/kg) on day 1, followed by a daily maintenance dose of 0.05 mg/kg orally, which should be tapered to the lowest effective dose (often 0.01–0.02 mg/kg) for long-term therapy.

Feline Chronic NSAID Management Checklist

To safely administer meloxicam chronically in cats under European guidelines, clinics should adhere to the following safety gates:

1. Baseline Screening: Perform a complete chemistry panel, urinalysis, and symmetric dimethylarginine (SDMA) screening to confirm stable renal function (IRIS Stage 1 or early Stage 2). Do not initiate if the cat is dehydrated or has unstable IRIS Stage 3 or 4 CKD.
2. Lowest Effective Dose: Taper the dose downward every 2–4 weeks. Many osteoarthritic cats can be successfully maintained on a fraction of the labeled dose.
3. Hydration Support: Advise owners to encourage water consumption through wet food diets, water fountains, and hydration supplements to maintain renal perfusion.
4. Routine Audits: Re-check serum chemistry, symmetric dimethylarginine (SDMA), and urine specific gravity every 3–6 months. Discontinue therapy if creatinine rises by $> 0.3$ mg/dL from baseline or if the cat develops vomiting or anorexia.

---

EMA Centralized Approvals and European Swine/Poultry Biologics

The European Medicines Agency (EMA) Union Register lists centrally authorized products under Boehringer Ingelheim's European entities (Boehringer Ingelheim Vetmedica GmbH and the legacy Merial business it acquired in 2017). Representative products from that register include:

1. Aftovaxpur DOE: An inactivated vaccine targeting Foot-and-Mouth Disease (FMD) virus, crucial for containment and biosecurity inside the EU.
2. Bovalto Ibraxion: Inactivated vaccine targeting Bovine Herpesvirus Type 1 (BHV-1) to prevent Infectious Bovine Rhinotracheitis (IBR) in cattle.
3. Ingelvac PCV FLEX: Subunit vaccine targeting Porcine Circovirus Type 2 (PCV2) to prevent post-weaning wasting syndrome in swine.
4. Parvoduk: Vaccine targeting Porcine Parvovirus.
5. Longrange (Eprinomectin): An extended-release injectable parasiticide for cattle providing up to 150 days of therapeutic concentration.
6. BTVPUR AlSap 2-4: Vaccine targeting Bluetongue Virus Serotypes 2 and 4.
7. Gripovac 3: Inactivated vaccine for swine influenza.
8. Certifect: A fipronil/amitraz topical parasiticide formulation for dogs.
9. BTVPUR AlSap 1: Vaccine targeting Bluetongue Virus Serotype 1.
10. BTVPUR Alsap 8: Vaccine targeting Bluetongue Virus Serotype 8.

Swine and Poultry Biologics Strategy

Boehringer's dominant position in European agriculture is supported by centralized biologics. In swine production, Ingelvac PCV FLEX allows piglets to be immunized at 3 weeks of age to prevent Porcine Circovirus Associated Diseases (PCVAD). Centralized licensing ensures that swine integrators can move animals across EU borders without facing regulatory delays from country-specific biological registration gaps, ensuring continuous biosecurity.

---

Senvelgo vs. Bexacat: choosing a veterinary SGLT2 inhibitor

Senvelgo (velagliflozin) is one of two SGLT2 inhibitors now marketed for feline diabetes; the other is Bexacat (bexagliflozin, Elanco). Because both drugs share the same mechanism and the same euglycemic-DKA failure mode, the choice between them is driven less by efficacy than by formulation, dosing flexibility, and the exact patient in front of you.

The clinical common ground is what matters most: both are indicated only for otherwise healthy, insulin-naïve diabetic cats with no ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at diagnosis. Neither replaces insulin, and in a cat that still needs insulin the liver keeps making ketones even while blood glucose looks controlled — the mechanism behind euglycemic DKA. In the velagliflozin field trial, DKA or eDKA occurred in roughly 5% of newly diagnosed cats and in about 18% of cats previously treated with insulin, and about 86% of those episodes clustered in the first two weeks of therapy. That is why ketone monitoring in the first 14 days, and an immediate stop-and-switch-to-insulin rule if ketones appear, is the central safety behavior for either product.

Where they differ is the operator experience:

• Formulation and dosing. Senvelgo is a once-daily oral liquid dosed by body weight, which suits cats that are difficult to pill and allows weight-based adjustment as the cat stabilizes. Bexacat is a fixed-dose tablet sized by weight band, which is simpler to dispense but less flexible for cats whose weight sits near a band boundary.
• Onset and monitoring. Both aim for glycemic improvement within about a week; in Senvelgo's SENSATION trial, blood glucose improved in most cats within the first week and polyuria/polydipsia had improved in over 50% by day 7. Both require the same structured urine-or-blood ketone checks in the first two weeks and a fructosamine recheck around week 4.
• Selection bottom line. If a cat is a good SGLT2 candidate (insulin-naïve, stable, eating, ketone-negative), either product can work; pick by formulation fit and owner ability to monitor. If the cat is not a good candidate, neither is appropriate — use insulin. VetMedGuide's SGLT2 inhibitor analysis walks through the dataset and the Senvelgo monitoring guide covers the day-by-day protocol.

Practice operations for a Boehringer-heavy formulary

Stocking Boehringer's companion-animal line efficiently means planning around three products that drive very different inventory and consent patterns.

• NexGard family. Afoxolaner chews are high-volume, fast-moving, and now compete directly with combination products (NexGard PLUS) and Zoetis's Simparica line. Stock by weight band, audit expiration dates monthly, and counsel owners that isoxazoline neurologic signs (tremors, ataxia, seizures) — though uncommon — are the event to watch for and report, especially in dogs with a seizure history.
• Vetmedin. With the Stage B2 indication now fully approved, clinics seeing cardiology cases should standardize their B2 staging workflow (murmur grade, VHS/VLAS, echo LA:Ao and LVIDd-N) before the first dose, because the benefit is Stage-B2-specific and starting a B1 dog offers no demonstrated gain. Pre-authorization of echocardiography and clear owner consent around "delaying CHF" versus "treating CHF" reduce both clinical and billing friction.
• Senvelgo. The biggest operational lift is client education: Senvelgo only works in the right cat, and the owner must commit to ketone checks in the first two weeks. Build a written protocol (baseline screening, day 2/3–7–14 rechecks, a "stop and call us if ketones appear" instruction, and an insulin fallback plan) before dispensing the first bottle. Documenting that consent and the ketone-monitoring plan also protects the clinic if a cat presents later with eDKA.

A simple way to keep the formulary honest: treat Senvelgo and Vetmedin as "staging-gated" drugs (no first dose without documented staging and consent) and NexGard as a "volume" drug (stock deep, counsel on neurologic signs). That split matches where Boehringer's portfolio generates the most post-market reporting and where the clinical risk concentrates.

Combination parasiticides and the MDR1 question

Boehringer's parasiticide line has shifted steadily toward combination products. NexGard PLUS stacks afoxolaner with milbemycin oxime to cover fleas, ticks, heartworm, and intestinal nematodes in a single monthly chew, and Heartgard Plus remains the long-standing ivermectin/pyrantel heartworm preventative. The clinical appeal is compliance — one product instead of two or three — but the macrocyclic-lactone components (milbemycin, ivermectin) bring a specific patient-safety consideration that clinics should build into their dispensing workflow.

Macrocyclic lactones are substrates for P-glycoprotein (P-gp), the efflux pump encoded by the ABCB1 (formerly MDR1) gene that protects the brain by pumping certain drugs back out of the central nervous system. Dogs homozygous for the ABCB1-1Δ mutation — classically Collies, Australian Shepherds, Shetland Sheepdogs, and related herding breeds — lack functional P-gp and can accumulate ivermectin and related drugs in the CNS, producing ataxia, depression, tremors, mydriasis, seizures, and in severe cases coma or death. For the low monthly heartworm-prevention doses used in NexGard PLUS or Heartgard Plus, the risk is low even in MDR1-affected dogs, and these products are generally considered safe at label doses. The danger concentrates at the high microfilaricidal or off-label demodicosis doses of ivermectin (hundreds of micrograms per kilogram), where the same mutation becomes clinically important.

The practical guidance: at standard preventative doses, ABCB1 status is not a reason to withhold Heartgard Plus or NexGard PLUS, but affected breeds should not receive high-dose ivermectin protocols without genotype testing, and any dog with a known ABCB1 mutation deserves a documented conversation before a macrocyclic-lactone product is dispensed off-label. This is the same P-gp mechanism that makes spinosad (Elanco's Comfortis/Trifexis) dangerous when combined with high-dose ivermectin — covered in the Elanco portfolio dossier — and it is why genotype-aware parasiticide selection cuts across company lines rather than sitting inside any one formulary.

FAQ: Common Clinical and Regulatory Questions

How does Senvelgo differ from insulin in safety monitoring protocols?

Traditional insulin therapy (such as glargine or Vetsulin) requires monitoring via blood glucose curves or interstitial glucose monitors (Freestyle Libre) to identify the nadir and duration of action, managing the risk of clinical hypoglycemia.

• Insulin Monitoring: Focuses on blood glucose levels and clinical signs of polyuria/polydipsia.
• Senvelgo Monitoring: Focuses on blood ketone levels (beta-hydroxybutyrate) rather than blood glucose. Because SGLT2 inhibitors lower blood glucose by default, blood glucose values do not indicate metabolic stability.
• Key Difference: If a cat on Senvelgo becomes lethargic or stops eating, checking blood glucose is insufficient; clinicians must check blood ketones to rule out euglycemic DKA.

Does Metacam carry different black-box warnings in Europe compared to the US?

Yes. There is a significant difference in labeling and regulatory warnings for meloxicam (Metacam) in cats between the US and the European Union:

• United States Label (FDA CVM): Carries a boxed warning stating that repeated use of meloxicam in cats has been associated with acute renal failure and death. The FDA approves Metacam in cats only as a single one-time subcutaneous injection for postoperative pain, with oral administration being off-label and discouraged.
• European Union Label (EMA): Approves oral meloxicam for chronic musculoskeletal disorders in cats. The Summary of Product Characteristics (SPC) allows long-term oral administration at a lower maintenance dose (0.05 mg/kg), provided the cat has stable renal function and undergoes regular blood monitoring.

This discrepancy highlights how regional regulatory bodies assess the risk-benefit ratio of NSAID therapy in feline patients differently, with the FDA taking a more conservative approach to post-market renal safety.

When is Senvelgo the wrong choice for a newly diagnosed diabetic cat?

Senvelgo is a good fit only for a narrow, well-defined patient: a clinically stable, hydrated, eating, insulin-naïve cat with no ketones and no concurrent pancreatitis. It is the wrong choice when any of those conditions fail, because the drug does not replace insulin and a cat that needs insulin will keep producing ketones on it. Specifically, do not start Senvelgo in a cat that is insulin-pretreated (markedly higher DKA risk on label), ketonuric or ketonemic at diagnosis, anorexic, dehydrated, or lethargic, or one with concurrent pancreatitis or significant renal/hepatic disease. In those cats, insulin (typically glargine or protamine zinc insulin) remains safer. The practical rule: if the cat looks sick, do not reach for an SGLT2 inhibitor.

How does afoxolaner (NexGard) compare to other isoxazolines for a dog with a seizure history?

Afoxolaner, fluralaner (Bravecto), sarolaner (Simparica), and lotilaner (Credelio) are all isoxazolines that act on insect GABA- and glutamate-gated chloride channels, and the class label for each carries a neurologic warning: tremors, ataxia, and seizures can occur, with or without a prior seizure history. The openFDA data bears this out — seizures are among the top-reported reactions for afoxolaner. For a dog with a known seizure disorder, the conservative move is not to pick the "safest" isoxazoline by reading report counts (those reflect usage volume and reporting, not head-to-head risk), but to discuss non-isoxazoline alternatives with the owner and, if an isoxazoline is still chosen, document the discussion and ensure seizure control is optimized first. VetMedGuide's NexGard side-effects analysis and the Bravecto vs NexGard comparison cover the class-level signal in more depth.

How should a clinic read Boehringer's post-market report numbers?

The single most important caveat is that these are passive reports, not incidence rates. A high report count for afoxolaner mostly reflects that tens of millions of doses have been sold; a high serious-flag rate for a product given to geriatric, multi-morbid patients mostly reflects that population. Reports also list every drug the animal was on, so a "pimobendan report" is frequently also a furosemide, ACE-inhibitor, and spironolactone report. Use the numbers to understand where to focus monitoring and client counseling, not to rank one drug against another as more or less dangerous.

What is the difference between NexGard and NexGard PLUS?

NexGard is a single-ingredient afoxolaner chew for fleas and ticks in dogs. NexGard PLUS adds milbemycin oxime, extending coverage to heartworm prevention and treatment and control of roundworms and hookworms in the same monthly chew. The clinical tradeoff is convenience versus breadth: NexGard PLUS suits owners who want one product for parasite protection, but it also means a dog receives a macrocyclic lactone every month, which matters for ABCB1/MDR1-affected breeds at anything above standard preventative doses. Owners should also confirm heartworm-negative status before starting any heartworm-preventative product, since administering a macrocyclic lactone to a heartworm-positive dog can trigger a reaction to dying microfilaria — a standard preventative-medicine step rather than a NexGard-specific concern. For a practice deciding between the single-ingredient and combination chews, the deciding factors are the patient's existing intestinal-parasite pressure, the owner's willingness to give a second product for heartworm if NexGard alone is chosen, and the MDR1 genotype if it is known.

---

Sources

• European Medicines Agency Union Register of Veterinary Medicinal Products: Centralized Authorizations for Boehringer Ingelheim Vetmedica GmbH. https://ec.europa.eu/health/documents/community-register/html/index_en.htm
• FDA Center for Veterinary Medicine (CVM) Approved Animal Drug Database: New Animal Drug Applications (NADA) for afoxolaner, pimobendan, telmisartan, and velagliflozin. https://www.fda.gov/about-fda/center-veterinary-medicine
• FDA CVM Drug Adverse Event Registry: Aggregated Pharmacovigilance Reports for afoxolaner, pimobendan, telmisartan, and velagliflozin (records processed through June 2026). https://www.fda.gov/animal-veterinary/safety-reports/adverse-drug-experience-reports
• American Animal Hospital Association (AAHA) Guidelines for Veterinary Practice Laboratory Diagnostics. https://www.aaha.org/for-veterinary-professionals/aaha-guidelines/
• The EPIC Study: Evaluation of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly (Boswood et al., 2016). Journal of Veterinary Internal Medicine. PMID 27678080 / PMC5115200. https://pmc.ncbi.nlm.nih.gov/articles/PMC5115200/